SILDENAFIL CITRATE- sildenafil tablet, film coated

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

SILDENAFIL CITRATE (UNII: BW9B0ZE037) (SILDENAFIL - UNII:3M7OB98Y7H)

Disponible depuis:

Advagen Pharma Ltd

Mode d'administration:

ORAL

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Sildenafil tablets were added to background epoprostenol therapy [see Clinical Studies (14)]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%). Limitation of Use : Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see Clinical Studies (14)]. Sildenafil tablets are contraindicated in patients with: -   Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the

Descriptif du produit:

Sildenafil Tablets, USP 20 mg are supplied as white round, biconvex film coated tablets debossed with "R" on one side and "20" on the other side, containing sildenafil citrate equivalent to the nominally indicated amount of sildenafil as follows: Recommended Storage for Sildenafil Tablets, USP: Store at 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].

Statut de autorisation:

Abbreviated New Drug Application

Résumé des caractéristiques du produit

SILDENAFIL CITRATE- SILDENAFIL TABLET, FILM COATED
ADVAGEN PHARMA LTD
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
SILDENAFIL TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
SILDENAFIL TABLETS.
SILDENAFIL TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1998
RECENT MAJOR CHANGES
Warnings and Precautions, Visual Loss ( 5.5) 7/2017
INDICATIONS AND USAGE
Sildenafil tablets are phosphodiesterase-5 (PDE-5) inhibitor indicated
for the treatment of pulmonary
arterial hypertension (PAH) (WHO Group I) in adults to improve
exercise ability and delay clinical worsening.
Studies establishing effectiveness were short-term (12 to 16 weeks),
and included predominately patients
with NYHA Functional Class II-III symptoms. Etiologies were idiopathic
(71%) or associated with connective
tissue disease (25%). ( 1)
Limitation of Use: Adding sildenafil to bosentan therapy does not
result in any beneficial effect on exercise
capacity. ( 1, 14)
DOSAGE AND ADMINISTRATION
Tablets: 20 mg three times a day, 4 to 6 hours apart ( 2.1)
DOSAGE FORMS AND STRENGTHS
_Tablets_ : 20 mg ( 3)
CONTRAINDICATIONS
Use with organic nitrates or riociguat ( 4)
History of hypersensitivity reaction to sildenafil or any component of
the tablet ( 4)
WARNINGS AND PRECAUTIONS
Increased mortality with increasing doses in pediatric patients. Not
recommended for use in pediatric
patients. ( 5.1)
Vasodilation effects may be more common in patients with hypotension
or on antihypertensive
therapy. ( 5.2)
Use in pulmonary veno-occlusive disease may cause pulmonary edema and
is not recommended. (
5.3)
Hearing or visual impairment: Seek medical attention if sudden
decrease or loss of vision or hearing
occurs. ( 5.5, 5.6)
Pulmonary hypertension secondary to sickle cell disease: Sildenafil
may cause serious vaso-occlusive
crises. ( 5.9)
ADVERSE REACTIONS
Most common adverse reactions greater than or equal to 3% and more
frequent than placebo were
epistaxis, headache, dyspepsia, flushing, in